Atopic Dermatitis: Clinical Trials

673 completed, 116 recruiting, 102 unknown, 84 terminated. 303 Phase 2, 209 Not applicable, 167 Phase 3, 159 Phase 1, 100 Phase 4.

By phase and status

Phase	Trials	Status
Phase 2	303	Completed 201, Terminated 35, Recruiting 24, Active not recruiting 16, Unknown 15, Withdrawn 7, Not yet recruiting 3, Enrolling by invitation 2
Not applicable	209	Completed 121, Unknown 28, Recruiting 18, Terminated 14, Withdrawn 12, Not yet recruiting 11, Active not recruiting 4, Enrolling by invitation 1
Phase 3	167	Completed 108, Recruiting 15, Unknown 10, Withdrawn 9, Active not recruiting 8, Not yet recruiting 8, Terminated 8, Enrolling by invitation 1
Phase 1	159	Completed 102, Terminated 17, Recruiting 15, Unknown 11, Withdrawn 7, Not yet recruiting 5, Active not recruiting 1, Enrolling by invitation 1
Phase 4	100	Completed 61, Unknown 10, Terminated 9, Not yet recruiting 8, Recruiting 6, Active not recruiting 3, Withdrawn 3
Early Phase 1	10	Completed 5, Unknown 2, Enrolling by invitation 1, Terminated 1, Withdrawn 1

Follow Atopic Dermatitis: new trials by email Literature Review of Atopic Dermatitis trials Research Report on Atopic Dermatitis

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients Skin Cleanser Combination No.1 - Atopic Dermatitis	Phase 4	Not yet recruiting	Boston Children's Hospital	100	2031-01-01	2026-03-10
Open-label Pilot Clinical Trial of Oral Ivermectin to Treat Atopic Dermatitis Ivermectin Pill - Atopic Dermatitis	Phase 2	Withdrawn	Stanford University		2030-12-01	2024-12-02
Determine the Dose-dependent Efficacy and Safety of EC-18 in Patients With Moderate to Severe Atopic Dermatitis EC-18, Placebo EC-18 - Atopic Dermatitis	Phase 2	Not yet recruiting	Enzychem Lifesciences Corporation	150	2027-05-01	2026-08-28
Abrocitinib Treatment of Atopic Dermatitis in Children 2 to Less Than 6 Years of Age Abrocitinib, Placebo - Atopic Dermatitis	Phase 3	Not yet recruiting	Pfizer	90	2027-05-01	2026-09-16
Opzelura Experience Study ruxolitinib, ruxolitinib and an Eczema Action Plan - Atopic Dermatitis	Phase 4	Not yet recruiting	Wake Forest University Health Sciences	50	2026-12-01	2026-09-04
Localized Aeroallergen Exposure in Atopic Dermatitis Localized grass pollen allergen exposure, Localized placebo exposure - Atopic Dermatitis	Not applicable	Not yet recruiting	Fraunhofer-Institute of Toxicology and Experimental Medicine	15	2026-12-01	2026-11-05
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis baricitinib - Hyper IgE Syndrome From STAT3 Mutation, Job s Syndrome	Phase 1	Recruiting	National Institute of Allergy and Infectious Diseases (NIAID)	20	2026-11-18	2026-11-13
Digital Mindfulness Meditation in Adolescents With Atopic Dermatitis Digital App Mindfulness Meditation, Mindfulness Meditation Sheet - Atopic Dermatitis, Eczema	Not applicable	Recruiting	Weill Medical College of Cornell University	40	2026-11-15	2026-10-23
AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of Patient-Centered Outcomes Lebrikizumab-lbkz - Atopic Dermatitis	Phase 4	Not yet recruiting	Forefront Dermatology S.C	250	2026-11-11	2026-10-02
Cosmetic Efficacy Evaluation of Hydraporin AI Cream in Individuals With Atopic Dermatitis and Psoriasis Investigational cream - Atopic Dermatitis, Psoriasis	Not applicable	Not yet recruiting	Brainfarma Industria Química e Farmacêutica S/A	42	2026-11-06	2026-11-05
A Phase I Study of GLR2053 Tablets in Chinese Healthy Adult Participants GLR2053 Tablets, Placebo - Atopic Dermatitis	Phase 1	Not yet recruiting	Gan & Lee Pharmaceuticals.	124	2026-11-05	2026-11-06
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis Lebrikizumab, Placebo - Atopic Dermatitis	Phase 3	Not yet recruiting	Almirall, S.A.	230	2026-11-01	2026-10-14
Efficacy and Tolerability of a Probiotic Ointment Probiotic Ointment, Comparator product - Atopic Dermatitis	Not applicable	Not yet recruiting	BioGaia AB	92	2026-11-01	2026-11-09
Roflumilast Cream 0.3% for Moderate to Severe Atopic Dermatitis Roflumilast Cream 0.3%, Vehicle Cream - Atopic Dermatitis, Atopic Dermatitis (AD)	Phase 3	Recruiting	Arcutis Biotherapeutics, Inc.	415	2026-10-30	2026-11-06
A Study to Investigate Dupixent/ Dupilumab in Adult Indian Participants With Moderate-to-severe Atopic Dermatitis Dupilumab - Atopic Dermatitis	Phase 4	Not yet recruiting	Sanofi	56	2026-10-28	2026-10-29
Observational Analytical Validation Study of the Replior ScratchSense Scratch and sleep research tracking - Atopic Dermatitis, Pruritus		Recruiting	Replior AB	35	2026-10-12	2026-11-04
Oral Melatonin as Adjunctive Therapy in Adults With Atopic Dermatitis Melatonin, Standard Treatment for Atopic Dermatitis - Atopic Dermatitis	Not applicable	Not yet recruiting	Can Tho University of Medicine and Pharmacy	130	2026-10-10	2026-09-25
Randomized, Double-blind, Placebo-controlled Study of Nemolizumab in Chinese Subjects With Moderate-to-severe Atopic Dermatitis Nemolizumab 30 mg, Placebo - Atopic Dermatitis	Phase 3	Recruiting	Galderma R&D	240	2026-10-08	2026-10-16
Abrocitinib Dose Tapering in Patients With Atopic Dermatitis Abrocitinib - Atopic Dermatitis	Phase 4	Not yet recruiting	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	100	2026-10-01	2026-09-29
Allergy, Asthma, and Atopic Eczema in Finland No intervention, No Intervention: Observational Cohort - Asthma, Asthma in Children		Enrolling by invitation	Tampere University	1600000	2026-10-01	2026-10-27

Showing 20 of 1114. Sign in to see all of them.

Narrower conditions

Dermatitis, Atopic (1114)  ·  Eczema (232)  ·  Psoriasis (61)  ·  Dermatitis (60)  ·  Pruritus (55)  ·  Skin Diseases (37)  ·  Asthma (33)  ·  Food Hypersensitivity (24)  ·  Hypersensitivity (21)  ·  Rhinitis, Allergic (21)  ·  Hidradenitis Suppurativa (16)  ·  Vitiligo (16)  ·  Alopecia Areata (14)  ·  Acne Vulgaris (10)  ·  Immune System Diseases (10)

Broader conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1114)  ·  Skin and Connective Tissue Diseases (1114)  ·  Genetic Diseases, Inborn (1112)  ·  Hypersensitivity, Immediate (1111)  ·  Skin Diseases, Genetic (1106)  ·  Immune System Diseases (1104)  ·  Skin Diseases, Eczematous (1104)  ·  Hypersensitivity (1093)  ·  Skin Diseases (1077)  ·  Dermatitis (1054)  ·  Pathological Conditions, Signs and Symptoms (88)  ·  Signs and Symptoms (65)  ·  Skin Diseases, Papulosquamous (65)  ·  Skin Manifestations (56)  ·  Respiratory Tract Diseases (45)

Interventions

dupilumab (63)  ·  pimecrolimus (30)  ·  lebrikizumab (23)  ·  upadacitinib (22)  ·  tralokinumab (20)  ·  abrocitinib (19)  ·  baricitinib (15)  ·  crisaborole (15)  ·  Adrenal Cortex Hormones (14)  ·  ruxolitinib (11)  ·  Cyclosporine (10)  ·  Ointments (10)  ·  Blood Specimen Collection (9)  ·  difamilast (9)  ·  Tacrolimus (8)

Sponsors

LEO Pharma (34)  ·  Pfizer (32)  ·  AbbVie (26)  ·  Eli Lilly and Company (26)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (24)  ·  Sanofi (19)  ·  Regeneron Pharmaceuticals (18)  ·  Northwestern University (16)  ·  Incyte Corporation (15)  ·  Amgen (14)  ·  Keymed Biosciences Co.Ltd (12)  ·  Novartis (12)  ·  Novartis Pharmaceuticals (12)  ·  Bayer (8)  ·  Fougera Pharmaceuticals Inc. (8)

Countries

United States (479)  ·  Germany (161)  ·  Canada (154)  ·  China (121)  ·  Poland (114)  ·  France (95)  ·  United Kingdom (83)  ·  Japan (80)  ·  Australia (77)  ·  Spain (75)  ·  Italy (56)  ·  South Korea (56)  ·  Netherlands (55)  ·  Taiwan (52)  ·  Czechia (51)

Top investigators

Amy Paller, MD (7)  ·  Angela C Kaplan (5)  ·  Donald Leung, MD, PhD (5)  ·  Richard Gallo, MD, PhD (5)  ·  Robert Bissonnette, MD (5)

Results publications

PMID 33826132, PMID 36255569, PMID 36749121, PMID 39588375, PMID 40555305, PMID 41118053, PMID 25006719, PMID 33165005, PMID 33658996, PMID 33982267, PMID 34275122, PMID 34688290, PMID 35714786, PMID 36152216, PMID 36525340, PMID 36723913, PMID 36754548, PMID 37043227, PMID 37247226, PMID 38777187, PMID 39110139, PMID 39441580, PMID 40085349, PMID 40383273, PMID 40457140, PMID 40600584, PMID 40875187, PMID 40900410, PMID 41206702, PMID 42530735, PMID 16895558, PMID 26343451, PMID 31066001, PMID 33000465, PMID 33222559, PMID 33305842, PMID 33453450, PMID 33899152, PMID 33957195, PMID 34023008, PMID 34142350, PMID 35262646, PMID 35567671, PMID 35636689, PMID 36264430, PMID 36808602, PMID 36920778, PMID 36994947, PMID 37682422, PMID 37804473

NIH funding

2018 (23), 2017 (12), 2025 (10), 2023 (9), 2014 (8), 2019 (8), 2016 (4), 2015 (3), 2008 (2), R21AR062357 (2), 2009 (1), R01AR071057 (1), R01AR073486 (1), R01AR082831 (1), R61AR084210 (1)